Jian Campian, MD
Medical Oncology · Rochester, MNNPI 1295979524
Payments from drug & device makers
What this record shows
The money is spread across several categories — speaking fees (57.6%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. Novocure Inc. accounts for 69.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2023 at $8,568 and has fallen 80.2% since, to $1,700 in 2024.
Across 22 payments — averaging $568.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novocure Inc.$9K
- Servier Pharmaceuticals LLC$2K
- Dova Pharmaceuticals$1K
- Monteris Medical Corporation$225
- Agios Pharmaceuticals, Inc.$185
- Incyte Corporation$162
- plus $224 from 3 others
Across 44 payments — averaging $166,173 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$6.7M
- Incyte Corporation$496K
- Beigene, Ltd.$37K
- Agios Pharmaceuticals, Inc.$36K
What the payments were for
- Consulting fees$3,06024%
- Speaking & faculty fees$7,20058%
- Travel & lodging$1,0448%
- Food & beverage$1,19610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novocure Inc. | 8 | $8,631 |
| Servier Pharmaceuticals LLC | 1 | $1,700 |
| Dova Pharmaceuticals | 2 | $1,373 |
| Monteris Medical Corporation | 2 | $225 |
| Agios Pharmaceuticals, Inc. | 1 | $185 |
| Incyte Corporation | 4 | $162 |
| Amgen | 2 | $114 |
| BTG International Inc. | 1 | $100 |
| Merck | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Optune$8,244
- DOPTELET$1,373
- Neuroblate$225
- Oncology$102
How this compares
$12,500 in reported general payments places this provider in the 70th percentile of 133 medical oncology providers in Minnesota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FycompaPerampanel | 12 | $14,848 |
| Dexamethasone | 37 | $664 |
| Levetiracetam | 19 | $580 |
| Ondansetron Hcl | 18 | $113 |
| Prochlorperazine Maleate | 11 | $96 |
| Omeprazole | 11 | $71 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in Rochester
- Amit MahipalRochester$746K
- Alton SartorRochester$688K
- Ben GeorgeRochester$579K
- Elisabeth HeathRochester$236K
- Matthew GoetzRochester$136K
- Thorvardur HalfdanarsonRochester$86K
- Harry YoonRochester$69K
- Karthik GiridharRochester$66K
- Joleen HubbardRochester$59K
- Lionel Aurelien Kankeu FonkouaRochester$58K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.